# US 2015/0309053 A1 · Test method and test kit for psychiatric ailments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0309053 A1
- Document ID: US20150309053A1
- Status: Published application
- Kind: A1
- Application number: 14/437,771
- Filed: 2013-10-23
- Published: 2015-10-29
- Earliest claimed: 2012-10-23
- Assignees: Riken; National University Corporation Hamamatsu University School of Medicine
- Applicants: Riken; National University Corporation Hamamatsu University School of Medicine
- Inventors: Takeo Yoshikawa; Motoko Maekawa; Norio Mori; Hideo Matsuzaki; Kazuhiko Nakamura
- Web page: https://patentgrep.com/patent/US20150309053A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2800/2814: Dementia; Cognitive disorders
- G01N 2800/38: Pediatrics
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/7085: Lipogenesis or lipolysis, e.g. fatty acid metabolism
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A novel test method for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder is provided. The test method includes a test step of determining an amount of at least one of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in a sample prepared from the living body of a human or determining an expression level of at least one of the FABP3, FABP4, FABP5, and FABP7 genes in the sample.

## Claims

### Claim 1

A test method for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder,
the test method comprising a test step of determining an amount of at least one of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in a sample prepared from the living body of a human or determining an expression level of at least one of the FABP3, FABP4, FABP5, and FABP7 genes in the sample.

### Claim 2 (depends on 1)

The test method as set forth in claim 1, wherein in the test step, the amount of the fatty acid binding protein FABP4 or the expression level of the FABP4 gene is determined.

### Claim 3 (depends on 1)

The test method as set forth in claim 1, wherein the sample is a blood-derived sample.

### Claim 4 (depends on 1)

The test method as set forth in claim 1, wherein the amount of the protein being tested is determined.

### Claim 5 (depends on 1)

The test method as set forth in claim 1, wherein the human is 8 years old or younger.

### Claim 6 (depends on 1)

The test method as set forth in claim 1, wherein in the test step, the presence of a predisposition to autistic spectrum disorder or the presence of development of autistic spectrum disorder is determined when at least one selected from among the amounts of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in the sample and the expression levels of the FABP3, FABP4, FABP5, and FABP7 genes in the sample is lower than that of a healthy subject.

### Claim 7 (depends on 1)

The test method as set forth in claim 1, wherein the autistic spectrum disorder is autism.

### Claim 8

A test kit for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder,
the test kit comprising a nucleic-acid probe, a nucleic-acid primer, a nucleic-acid aptamer, an antibody, or a peptide probe for detecting at least one of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in a sample prepared from the living body of a human or at least one of expression products of the FABP3, FABP4, FABP5, and FABP7 genes in the sample.
